Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza A Group 1 and Group 2 mRNA Chimeric Hemagglutinin Vaccines in Healthy Adults
NCT07703514Phase 1Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of cH15/3, cH5/1N1 and cH8/1N1 in influenza (6 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Geometric mean fold rise from baseline in HA-stalk specific titers, Geometric mean titer and 11 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
cH15/3cH5/1N1cH8/1N1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07703514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07703514.